不同而已
10-24
$东阳光长江药业(01558)$
基于创新管线的持续兑现与业绩增长预期,招商证券预测东阳光药2025-2027年归母净利润将显著改善,并首次覆盖给予“强烈推荐”评级。
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":492582545265072,"tweetId":"492582545265072","gmtCreate":1761280276031,"gmtModify":1761282207834,"author":{"id":4108712309198120,"idStr":"4108712309198120","authorId":4108712309198120,"authorIdStr":"4108712309198120","name":"不同而已","avatar":"https://static.tigerbbs.com/98e0561e98a4f7ea5f1a403dfcc3aaf9","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/01558\">$东阳光长江药业(01558)$ </a>基于创新管线的持续兑现与业绩增长预期,招商证券预测东阳光药2025-2027年归母净利润将显著改善,并首次覆盖给予“强烈推荐”评级。</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/01558\">$东阳光长江药业(01558)$ </a>基于创新管线的持续兑现与业绩增长预期,招商证券预测东阳光药2025-2027年归母净利润将显著改善,并首次覆盖给予“强烈推荐”评级。</p></body></html>","text":"$东阳光长江药业(01558)$ 基于创新管线的持续兑现与业绩增长预期,招商证券预测东阳光药2025-2027年归母净利润将显著改善,并首次覆盖给予“强烈推荐”评级。","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/492582545265072","repostId":0,"isVote":1,"tweetType":1,"viewCount":258,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["01558"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":141,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/492582545265072"}
精彩评论